Literature DB >> 12362577

Pathogenesis of autoimmune hepatitis.

Diego Vergani1, Kaushik Choudhuri, Dimitrios P Bogdanos, Giorgina Mieli-Vergani.   

Abstract

Autoimmune hepatitis is initiated by CD4 T cells that recognize self-antigen. The effector cells differentiate into functional phenotypes according to cytokines in the microenvironment and the nature of the triggering antigen. Hepatocytes can express class II molecules and present antigenic peptides through a bystander mechanism. NKT cells reside in the normal liver but may be involved in liver cell damage possibly through the expression of Fas ligand. Autoantibodies may also participate in the process by complexing with antigen on the hepatocyte membrane surface and by interacting with mononuclear cells with Fc receptors. Molecular mimicry generates cross-reactivities that predispose the immune system to cross-react with self-antigens. Multiple exposures to pathogens with antigenic similarities may prime a cross-reactive subset of T cells in the genetically predisposed host. Autoimmunity against one self-antigen may then spread through molecular mimicry to other homologous self-antigens and may lead to overt autoimmune disease. Anatomically distant tissues may also become involved as autoreactive T cells that had been activated in one organ expand and infiltrate other organs that express similar epitopes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12362577     DOI: 10.1016/s1089-3261(02)00018-1

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  34 in total

1.  Mouse models of liver fibrosis mimic human liver fibrosis of different etiologies.

Authors:  Allyson K Martínez; Luca Maroni; Marco Marzioni; Syed T Ahmed; Mena Milad; Debolina Ray; Gianfranco Alpini; Shannon S Glaser
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

Review 2.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

Review 3.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

Review 4.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 5.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

Review 6.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

Review 7.  Case Report: Acute Hepatitis E in a Pediatric Traveler Presenting with Features of Autoimmune Hepatitis: A Diagnostic and Therapeutic Challenge.

Authors:  Nathan Z Minkoff; Kate Buzzi; Alex K Williamson; Stefan H F Hagmann
Journal:  Am J Trop Med Hyg       Date:  2019-01       Impact factor: 2.345

8.  A Case of Autoimmune Hepatitis Treated with Rituximab.

Authors:  E Barth; J Clawson
Journal:  Case Rep Gastroenterol       Date:  2010-11-23

Review 9.  Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?

Authors:  Daniel Smyk; Eirini I Rigopoulou; Yoh Zen; Robin Daniel Abeles; Charalambos Billinis; Albert Pares; Dimitrios P Bogdanos
Journal:  World J Gastroenterol       Date:  2012-09-21       Impact factor: 5.742

Review 10.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.